NEW YORK (360Dx) – Abreos Biosciences today announced a collaboration with ResearchDx to make a test for monitoring Tysabri (natalizumab) available to clinicians and clinical trial partners.
The test, called moNATor, will be available through Pacific Diagnostics, ResearchDx's CLIA-approved and CAP-accredited and reference laboratory. The assay was developed by Abreos Bio and ResearchDx to monitor Tysabri, a humanized anti-α4 monoclonal antibody for treating relapsing-remitting multiple sclerosis and Crohn's disease. Prolonged use of the drug, along with other risk factors, have been associated with an increased risk for progressive multifocal leukoencephalopathy, and clinicians can use noMATor to monitor levels of active Tysabri throughout the therapy.
Financial and other terms of the deal were not disclosed.
ResearchDx is a companion diagnostics organization that designs, develops, manufactures, and commercializes diagnostic testing for the clinical, clinical research, and biopharmaceutical industries. Abreos Bio develops technologies aimed at precision dosing of biological therapeutics.